0001140361-23-024002.txt : 20230511 0001140361-23-024002.hdr.sgml : 20230511 20230511072055 ACCESSION NUMBER: 0001140361-23-024002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVROBIO, Inc. CENTRAL INDEX KEY: 0001681087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 810710585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38537 FILM NUMBER: 23908812 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 6TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617.914.8420 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 6TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AvroBio, Inc. DATE OF NAME CHANGE: 20160729 8-K 1 brhc20052752_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 11, 2023


AVROBIO, INC.
(Exact name of registrant as specified in its charter)
 

Delaware
001-38537
81-0710585
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

100 Technology Square
Sixth Floor
Cambridge, MA 02139
(Address of principal executive offices, including zip code)
 
(617) 914-8420
(Registrant’s telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
  
Trading
symbol(s)
  
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share
  
AVRO
  
Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.
 
On May 11, 2023, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three months ended March 31, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

Press release issued by AVROBIO, Inc., dated May 11, 2023.
   
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
AVROBIO, INC.
     
Date: May 11, 2023
By:
/s/ Erik Ostrowski
   
Erik Ostrowski
   
President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer


EX-99.1 2 brhc20052752_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

AVROBIO Reports First Quarter 2023 Financial Results and
Provides Business Update

On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment

Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment

Collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated

Announced appointment of current CFO Erik Ostrowski as interim CEO

CAMBRIDGE, Mass., May 11, 2023 -- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the first quarter ended March 31, 2023, and provided a business update.

“We look forward to building upon last year’s positive data and regulatory updates for our lead programs and demonstrating the potential of our HSC gene therapy approach in the year ahead,” said Erik Ostrowski, interim CEO and current CFO of AVROBIO. “We plan to initiate a global, registrational Phase 2/3 trial of our Gaucher disease type 3 (GD3) program later this year and are happy to report that our collaborator-sponsored Phase 1/2 trial for Hunter syndrome has recently commenced enrollment.  Additionally, we plan to provide an update on our cystinosis program in mid-May at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.”

Program Highlights and Milestones

AVR-RD-02 for Gaucher disease:

 •
“The Guard1 clinical trial – A first in-human, Phase 1/2 study evaluating AVR-RD-02, an HSC gene therapy for Gaucher disease: Preliminary safety, pharmacodynamic and clinical efficacy results from the subjects observed for up to 24 months post-infusion” -- AVROBIO presented safety and efficacy data at the 19th annual WORLDSymposium™, Feb. 22-26, 2023.

•
Guard1 is recruiting individuals between the ages of 16 and 50 with Gaucher disease type 1 (GD1), including those who are treatment-naïve and who are stable on enzyme replacement therapy, with sites in Canada and the U.S.

•
“Sustained improvement of clinical CNS and somatic features of GD3 after HSC gene therapy: A first-in-world report” -- Clinical data from the first pediatric GD3 patient, dosed with investigational AVR-RD-02, was presented by one of the patient’s physicians from the University of Manchester (UoM), U.K. at WORLDSymposium™. New data included longer time points for peripheral blood glucocerebrosidase, chitotriosidase and albumin levels, all trending consistently with previously presented data. The 11-year-old GD3 patient was dosed at UoM on a named patient basis.


•
Plan to initiate Guard3, a global registrational Phase 2/3 trial for GD3, in the second half of 2023, subject to regulatory alignment.

•
AVR-RD-02 has been granted Rare Pediatric Disease Designation and Fast Track Designation by FDA, Orphan Drug Designation in the U.S. and U.K., and an Innovation Passport by MHRA under the Innovative Licensing and Access Pathway (ILAP).

AVR-RD-04 for cystinosis:

 •
“Phase 1/2 clinical trial of autologous hematopoietic stem and progenitor cell (HSPC) gene therapy for cystinosis” -- Collaborators at the University of California, San Diego,1 presented updated data on the six patients dosed in the fully enrolled Phase 1/2 clinical trial at WORLDSymposium™, including additional vector copy number (VCN) data, as well as longer time points for leukocyte cystine levels and skin and GI mucosa cystine crystal data, for some patients. All clinical and safety data updates are trending consistently with the prior reported data as of the most recent safety data cut-off date of Jan. 9, 2023.

•
Plan to provide a clinical and regulatory update on the cystinosis program at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in mid-May 2023.

•
Plan to initiate activities for the Phase 1/2 clinical trial in the second half of 2023 subject to regulatory alignment.

•
AVR-RD-04 has been granted Rare Pediatric Disease Designation and Fast Track Designation by FDA and Orphan Drug Designation in the U.S. and U.K.

AVR-RD-05 for neuronopathic mucopolysaccharidosis type II (MPS-II), or Hunter syndrome:

 •
Collaborator-sponsored Phase 1/2 clinical trial for neuronopathic mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated.

•
“Validation of a GMP stem cell gene therapy manufacturing process for mucopolysaccharidosis type II (MPS II) in preparation for an approved Phase 1/2 clinical trial” -- Collaborators at UoM highlighted data validating their manufacturing process in preparation for a Phase 1/2 clinical trial for Hunter syndrome anticipated to start later this year at WORLDSymposium.

•
AVR-RD-05 has been granted Rare Pediatric Disease Designation and Orphan Drug Designation by FDA.

1 Collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 is funded in part by grants to UCSD from the California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation (CRF) and National Institutes of Health (NIH).

AVR-RD-03 for Pompe disease:

 •
AVR-RD-03 is currently being evaluated in a pre-clinical research program and the data to-date have shown significantly reduced toxic accumulation of glycogen in a mouse model of Pompe disease, including in cardiac and skeletal muscle as well as the central nervous system (CNS).

Organizational Update
On May 1, 2023, AVROBIO announced the appointment of Erik Ostrowski as interim CEO. Mr. Ostrowski, who will continue as AVROBIO’s CFO, succeeds founding president and CEO Geoff MacKay, who left to join an emerging early-stage company. The Board of Directors has begun a search to identify a permanent CEO.

First Quarter 2023 Financial Results
AVROBIO reported a net loss of $25.0 million for the first quarter of 2023 as compared to a net loss of $29.8 million for the comparable period in 2022.

Research and development expenses were $17.3 million for the first quarter of 2023 as compared to $19.3 million for the comparable period in 2022. This decrease was driven by a reduction in personnel-related costs, including non-cash stock-based compensation, and partially offset by an increase in program development expenses.

General and administrative expenses were $7.9 million for the first quarter of 2023 as compared to $10.2 million for the comparable period in 2022. This decrease was driven by a decrease in personnel-related costs, including non-cash stock-based compensation.

Other income (expense), net was $0.3 million for the first quarter of 2023 as compared to other (expense) income, net of ($0.4) million for the comparable period in 2022. This increase in other income is due to an increase in interest income which was partially offset by interest expense related to our term loan.

As of March 31, 2023, AVROBIO had $72.3 million in cash and cash equivalents, as compared to $92.6 million in cash and cash equivalents as of Dec. 31, 2022. Based on AVROBIO’s current operating plan, AVROBIO expects its cash and cash equivalents as of March 31, 2023, will enable AVROBIO to fund its operating expenses and capital expenditure requirements into the first quarter of 2024.

About AVROBIO
Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for Gaucher disease, cystinosis and Hunter syndrome, as well as a preclinical program for Pompe disease. Our proprietary plato® gene therapy platform is scalable for planned global commercialization. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statement
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by forward-looking terminology such as “aims,” “anticipates,” “believes,” “continue,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,” “strives,” “should,” “will,” and similar expressions or the negative of these terms. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our current and prospective preclinical and clinical product candidates, the expected safety profile of our investigational gene therapies, results of preclinical studies, the design, commencement, enrollment and timing of ongoing or planned clinical trials, preclinical, compassionate use or clinical trial results, product approvals and regulatory pathways, the timing of patient recruitment and enrollment activities, our expectations with respect to our plans with collaborators, our plans and expectations with respect to interactions with regulatory agencies and the timing and likelihood of success thereof, the expected benefits and results of our implementation of the plato® platform in our clinical trials and gene therapy programs and its potential impact on our manufacturing and commercialization activities, statements regarding a leadership transition including the appointment of an interim CEO and our search to identify a permanent CEO, and statements regarding our financial and cash position and expected cash runway, including impact on anticipated milestones. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that we may be unable to realize the potential benefits associated with rare pediatric disease designation, the Innovative Licensing and Access Pathway, or any other regulatory strategy, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, including sole source suppliers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements, needs for additional financing, and ability to continue as a going concern including the risk that additional funding may not be available on acceptable terms or at all and that failure to obtain capital when needed may force us to delay, limit or terminate our product development efforts or other operations, risks relating to our identification and pursuit of any strategic opportunities with respect to one or more of our programs, our technology or our plato® platform, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Annual or Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investor Contact:
Christopher F. Brinzey
Westwicke, an ICR Company
339-970-2843
chris.brinzey@westwicke.com

Media Contact:
Kit Rodophele
Ten Bridge Communications
617-999-9620
krodophele@tenbridgecommunications.com

CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)

 
March 31,
2023
    
December 31,
2022
  
             
Cash and cash equivalents
  
$
72,326
    
$
92,563
  
Prepaid expenses and other current assets
    
4,925
      
7,112
  
Property and equipment, net
    
2,574
      
2,894
  
Operating lease assets
    
2,857
      
1,057
  
Other assets
    
323
      
323
  
Total assets
  
$
83,005
    
$
103,949
  
                 
Accounts payable
  
$
591
    
$
384
  
Accrued expenses and other current liabilities
    
11,081
      
11,732
  
Note payable, net of discount
    
15,356
      
15,276
  
Operating lease liabilities
    
2,979
      
1,187
  
Total liabilities
    
30,007
      
28,579
  
                 
Total stockholders’ equity
    
52,998
      
75,370
  
Total liabilities and stockholders’ equity
  
$
83,005
    
$
103,949
  

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

   
Three Months Ended
March 31,
  
   
2023
    
2022
  
             
Operating expenses:
            
Research and development
  
$
17,333
    
$
19,253
  
General and administrative
    
7,887
      
10,165
  
Total operating expenses
    
25,220
      
29,418
  
                 
Loss from operations
    
(25,220
)
    
(29,418
)
Other income (expense), net
    
263
      
(415
)
Net loss
  
$
(24,957
)
  
$
(29,833
)
Net loss per share — basic and diluted
  
$
(0.57
)
  
$
(0.68
)
Weighted-average number of common shares outstanding — basic and diluted
    
44,037
      
43,695
  


EX-101.SCH 3 avro-20230511.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avro-20230511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 avro-20230511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 11, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 11, 2023
Entity File Number 001-38537
Entity Registrant Name AVROBIO, INC.
Entity Central Index Key 0001681087
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-0710585
Entity Address, Address Line One 100 Technology Square
Entity Address, Address Line Two Sixth Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 914-8420
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AVRO
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 7 brhc20052752_8k_htm.xml IDEA: XBRL DOCUMENT 0001681087 2023-05-11 2023-05-11 false 0001681087 8-K 2023-05-11 AVROBIO, INC. DE 001-38537 81-0710585 100 Technology Square Sixth Floor Cambridge MA 02139 617 914-8420 false false false false Common Stock, $0.0001 par value per share AVRO NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://avrobio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc20052752_8k.htm avro-20230511.xsd avro-20230511_lab.xml avro-20230511_pre.xml brhc20052752_ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc20052752_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "brhc20052752_8k.htm" ] }, "labelLink": { "local": [ "avro-20230511_lab.xml" ] }, "presentationLink": { "local": [ "avro-20230511_pre.xml" ] }, "schema": { "local": [ "avro-20230511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avro", "nsuri": "http://avrobio.com/20230511", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc20052752_8k.htm", "contextRef": "c20230511to20230511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://avrobio.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc20052752_8k.htm", "contextRef": "c20230511to20230511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://avrobio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001140361-23-024002-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-024002-xbrl.zip M4$L#!!0 ( )LZJU;UJC8H10, #8/ 1 879R;RTR,#(S,#4Q,2YX M''9,+NN=E^+ MJ4!+G$$@(5]@^05F6.00X9FSE#*?^CY\X6Q.F(=8YD=!- K&8:CDI#C#5-XS MGMWB!!:IG#E_"IB2A.#8 4H_%=.UJ%E6JY6W&GF,+Q1)$/H_/S]^,W$M5H=Y M)68)3 G]W:)=SWEJB4>^-L^AP+6&'7PE(YQ,)KZQUE!%1(Y0$RHDI @W\;&L M'9K@L5\:+52=F=SD>)N/!(JY 5N+WF=DX8++0_C:U'*(,6GK$!AY"_;B*T,; M*'F'N;5/9?:U6?L$;A"Z4>BH,@% %PJDE$DH54V:I6HQSPE-6+6BUG1&I_84 MGG$"3(ZGFG7F")+EJ4Z@65MRG,P5?.<>>DFHAG*7XR)%HLZ]3_LVVE<-YW6\H%I_]W/YKGN]H!T(,? MSP][&]"(N66HT W_@<9W5!*Y>5"'SC.3

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